Introduction
Vildagliptin is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycemic control in patients with type 2 diabetes (T2DM) when given as monotherapy (1) (2) (3) , or in combination with metformin (4), thiazolidinediones (5, 6) , sulfonylureas (7) , or insulin (8) . By inhibiting DPP-4, vildagliptin increases plasma levels of the intact, active form of glucagon-like peptide-1 (GLP- 1) and gastric inhibitory polypeptide (GIP) (8) (9) (10) (11) (12) (13) . The glucose-dependent insulinotropic effects of both GLP-1 and GIP, as well as the glucagonostatic effect of GLP-1, are thought to underlie the therapeutic efficacy of vildagliptin (5, 6, (8) (9) (10) (11) (12) (13) .
The relative contributions of improvements in α-and β-cell function are debatable. However, the correlation between the suppression of the glucagon response to meal ingestion and the improved glucose tolerance after treatment with vildagliptin (9) , and the observation that vildagliptin significantly reduced 1c A 1c (HbA 1c in patients with T2DM treated with high-dose (>80 U/d) insulin monotherapy (8) clearly indicate that the contribution of glucagon suppression is not negligible. Because of the critical role that glucagon plays in the prevention or correction of hypoglycemia (14) , it was possible that suppressing glucagon secretion with vildagliptin would predispose insulin-treated patients to hypoglycemia. However, hypoglycemia was less frequent and less severe when vildagliptin was given as an add-on to insulin (vsplacebo added to insulin), suggesting that vildagliptin may exert a protective effect against severe hypoglycemia (8) . Accordingly, we hypothesized that vildagliptin would increase the glucagon response to hypoglycemia while suppressing glucagon during hyperglycemia in patients with T2DM. To test this hypothesis, the present study was performed with drug-naїve patients with T2DM and mild hyperglycemia (HbA 1c ≤7.5%). After 28-d treatment with vildagliptin (100 mg qd) or placebo, standard breakfast meal tests were performed, followed by stepped glucose clamps (7.5, 5.0, and 2.5 mmol/liter glucose).
Research Design and Methods
Study design. This was a single-center, double-blind, randomized, placebo-controlled, crossover study of 28-d treatment with vildagliptin (100 mg qd) with a 4-wk between-treatment washout period. Each patient Page 4 of 25 attended one screening visit (Week -4), during which inclusion/exclusion criteria were assessed. Eligible patients were randomized at visit 2 (Day 1) and expected to complete two treatment periods, receiving a different blinded study medication during each period (vildagliptin 100 mg qd and placebo, in random order). At the baseline (Day 1) visit of each treatment period, HbA 1c , fasting plasma glucose (FPG), and baseline safety assessments were made and study medication was dispensed for 4 weeks of outpatient treatment.
The test procedure (see below) was performed after an overnight fast, on Day 28 of the first treatment period. Study medication was then discontinued, and a 4-wk washout period occurred before the alternative treatment period. The test procedure was repeated on Day 28 of the second treatment period.
Study population. The study enrolled male and female patients (females of childbearing potential required to use a medically approved birth control method) aged ≥18 yr; with a body mass index (BMI) Between-treatment differences in each of the aforementioned variables were made with paired t tests in the completers population. Because the "direction" of change in each parameter was predicted (hypothesized) before study inception, one-sided tests were performed, with a 0.05 significance level.
Ethics and good clinical practice. The protocol was approved by the ethics committee of Lund
University, Sweden, and all subjects gave written informed consent before entering the study. The study was conducted using good clinical practice and in accordance with the Declaration of Helsinki.
Results
Patients studied. Thirty-two patients were screened, 30 were randomized (15 to each treatment sequence), and 25 patients comprised the completers population, defined as all randomized patients who received at least one dose of study drug and had a valid assessment of the primary variable at the end of each treatment period. Of the 30 randomized patients, 2 had no valid primary efficacy assessment during the double-blind treatment period, 2 had only one valid primary efficacy assessment during the doubleblind treatment period, and 1 had hyperglucagonemia (pre-meal glucagon levels >200 ng/liter during both treatment periods); thus, these 5 subjects were excluded from the completers population. Table 1 summarizes the demographic and baseline characteristics of the completers population.
Patients were all Caucasian and predominantly male, with a mean age, BMI, disease duration, and baseline 1c HbA 1c of approximately 66 years, 28 kg/m 2 , 6 years, and 6.3%, respectively. Patients randomized to treatment sequence A (vildagliptin, then placebo) had somewhat higher baseline levels of HbA 1c and FPG, and somewhat longer disease duration than did patients randomized to treatment sequence B (placebo, then vildagliptin). However, these modest differences should be of no significance because every patient received both treatments, and there was a 4-wk washout period between treatments.
Standard meal tests. Figure 1 depicts the time-courses of glucose, GLP-1, glucagon, and ISR during the standard meal test that was performed immediately before the stepped glucose clamp. It may be appreciated that relative to placebo, vildagliptin treatment was associated with lower FPG and postprandial glucose levels and fasting and postprandial glucagon levels, with greatly enhanced fasting and postprandial plasma levels of intact GLP-1, but essentially no effect on absolute ISR. Table 2 summarizes the integrated responses to the standard meal. Vildagliptin significantly increased the GLP-1 response and significantly decreased the glucagon response to meals, whether expressed as total secretion, or the incremental response, integrated over the first hour of sampling, or the entire post-meal sampling period. Similarly, postprandial glucose levels were significantly decreased during vildagliptin treatment.
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The incremental ISR was significantly increased when integrated over the first 60 min, but the absolute ISR was unaffected if the total AUC was considered, regardless of the time interval used, and the incremental insulin response integrated over the 2-h post-meal period showed only a slight trend toward an increase with vildagliptin vs placebo administration. In contrast, insulin secretion relative to glucose was significantly increased, whether integrated over the first 60 min or the entire 2-h post-meal sampling period, and whether the total responses or the incremental responses were considered. Again, the percentage changes in the incremental AUCs were greater than the percentage changes in the total AUCs.
Hyperinsulinemic stepped glucose clamps. Figure 2 depicts plasma glucose and glucagon levels, and the ISR during the hyperinsulinemic stepped glucose clamps initiated immediately after the standard meal tests on Day 28 of both treatment periods. It can be seen that, although plasma glucose levels were significantly lower in the vildagliptin treatment period during the hyperglycemic step, plasma glucose levels were well matched during the euglycemic and hypoglycemic steps, and plasma glucose levels recovered in <1 h in both treatment periods. Plasma glucagon levels were suppressed during the hyperglycemic step in the vildagliptin treatment period, despite significantly lower plasma glucose levels, and remained suppressed during the euglycemic step. However, during the hypoglycemic clamp step, plasma glucagon levels increased from a significantly lower level at time 210 min, to a level slightly higher and not significantly different at the end of the hypoglycemic clamp (time 255 min) during vildagliptin treatment when compared with placebo administration. Thus, as reported in Table 3 , the increase in glucagon during hypoglycemia with vildagliptin (change = 46.7 ± 6.9 ng/liter) was significantly greater than the increase during hypoglycemia with placebo (change = 33.9 ± 6.7 ng/liter,
P=0.039 vs vildagliptin).
The ISR was significantly higher during vildagliptin treatment from times 165 to 255 min of the stepped clamp; (ie, during euglycemia and hypoglycemia) (Figure 2 Safety and tolerability. The overall adverse event (AE) profiles during treatment with vildagliptin were similar to those during placebo administration. No specific AE was reported by more than 3 patients during either treatment period, and the only AE reported by 3 patients was nasopharyngitis, which occurred during both treatment periods (ie, during placebo and during vildagliptin). No serious AE (SAE) was experienced by any patient during vildagliptin treatment; during placebo administration, 3 patients experienced an SAE: one case of appendicitis, one of infective arthritis, and one myocardial infarction.
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Discontinuations due to an AE were limited to one case of decreased appetite in a patient receiving vildagliptin, and the myocardial infarction experienced by a patient receiving placebo. There were no hypoglycemic events or asymptomatic low blood glucose reported during either treatment.
Discussion
Glucagon secretion is stimulated by hypoglycemia and suppressed by hyperglycemia; in healthy subjects, the glycemic threshold for stimulation of glucagon release is approximately 4 mmol/liter.
Numerous factors in addition to glucose can influence glucagon secretion and potentially contribute to the pathophysiology of glucagon secretion that occurs in T2DM (15) . For example, epinephrine, sympathetic and parasympathetic neurotransmitters, amino acids, and several gut hormones (eg, cholecystokinin, gastrin-releasing peptide) stimulate glucagon secretion, whereas free fatty acids and ketones, gut hormones (eg, GLP-1, secretin), as well as locally released insulin and pancreatic somatostatin inhibit glucagon secretion. Indeed, it has been suggested that locally released insulin mediates the suppressive effects of hyperglycemia on glucagon secretion (16) .
Abnormalities of glucagon secretion occur in patients with impaired glucose tolerance (IGT) and T2DM, and most abnormalities, if not all, may actually reflect an impairment of α-cell glucose sensing (15, 17, 18) , (ie, an impaired ability of glucose to suppress glucagon secretion) (15, 17, 18) .
A new class of OADs, the DPP-4 inhibitors, has been developed for the treatment of T2DM (19) .
The efficacy of DPP-4 inhibitors, such as vildagliptin, is attributable in part to a GLP-1-mediated glucagonostatic effect (10, 11, 20) . However, if these agents suppressed glucagon secretion under all conditions, they could predispose patients to hypoglycemia; this, however, has not been observed. In fact, all clinical experience with DPP-4 inhibitors to date suggests that they have a low propensity to induce
hypoglycemia. An earlier study in healthy volunteers suggested that short-term infusion of the incretin mimetic exenatide augmented the glucagon response to severe hypoglycemia (21) , and another study found that vildagliptin added to high-dose insulin therapy in patients with T2DM actually decreased the incidence and severity of hypoglycemia (8) . Consequently, we hypothesized that vildagliptin would enhance the ability of the α-cell to sense and respond appropriately to changes in plasma glucose concentrations.
To test this hypothesis we examined the influence of 28-d treatment with vildagliptin (100 mg qd) on the glucagon response to both hyperglycemia and hypoglycemia in patients with T2DM and mild hyperglycemia (HbA 1c =6.3%). As expected, and shown previously (9-12), vildagliptin suppressed inappropriate glucagon secretion during meals. Further, plasma glucagon levels remained suppressed not only during the hyperglycemic step, but also during the euglycemic step of the clamp. Thus, the enhanced response to hypoglycemia during vildagliptin treatment reflected solely the significantly lower initial levels (at time 210 min). Nonetheless, the present finding of an increase from a significantly lower level to a slightly higher glucagon level during the hypoglycemic step with vildagliptin vs placebo clearly
indicates that the α-cell response to hypoglycemia was not impaired. Indeed, the finding that the increment in plasma glucagon concentrations during hypoglycemia with vildagliptin was 38% higher than with placebo could be interpreted as an enhanced response. Since the duration of each glucose step was only 45 min, and an apparent "steady-state" hypoglycemia was maintained for only 10 min, it remains to be determined if a more sustained period of hypoglycemia would reveal a truly enhanced response with significantly higher glucagon levels with vildagliptin vs placebo.
Several additional findings from this study may shed light on the mechanisms underlying the greater increase in glucagon with vildagliptin vs placebo. During the hypoglycemic step of the clamp, the timing and degree of hypoglycemia were essentially identical during the two treatment periods, and the increases in epinephrine, norepinephrine, and cortisol also were unaffected by vildagliptin treatment. This suggests that, as intended, equivalent "stress" was induced by hypoglycemia during the two treatment periods. However, activation of the parasympathetic nervous system appears to have been augmented by vildagliptin treatment. Circulating PP levels are considered to be an index of parasympathetic nervous system activity (22) , and, in the present study, the mean PP response to hypoglycemia increased by >80% during vildagliptin treatment; the trend approached, but did not achieve, statistical significance.
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The strong trend toward an increase in the PP response to hypoglycemia with vildagliptin treatment suggests that increased vagal activity may mediate, or contribute to, the enhanced glucagon response. This would be consistent with the growing body of literature suggesting that many of the actions often ascribed to circulating GLP-1 may in fact be mediated by neuronal mechanisms (23) (24) (25) (26) (27) (28) .
The present study also found that the decrease of ISR during hypoglycemia was more pronounced with vildagliptin than with placebo, ie, ISR decreased from a significantly higher level at time 210 min to an identical level at 285 min with the change (reduction) in ISR during hypoglycemia being significantly greater with vildagliptin than with placebo. To our knowledge, this is the first demonstration that an agent presumably acting through GLP-1 receptor signaling enhances the effectiveness of low glucose levels to suppress insulin secretion. Although some would argue that this observation supports the concept that glucose control of glucagon secretion is mediated by local insulin levels (29-31), we have recently shown that vildagliptin suppresses postprandial glucagon levels in insulinopenic patients with type 1 diabetes (32). Thus, although enhanced suppression of insulin secretion may have contributed to the enhanced glucagon response to hypoglycemia seen with vildagliptin treatment, understanding the mechanisms underlying the effects on both insulin and glucagon secretion will require further study. Independent of the exact underlying mechanisms, the present study provides evidence that DPP-4 inhibition with vildagliptin improves (or restores) the ability of both α-and β-cells to sense and respond appropriately to changes in plasma glucose levels.
Vildagliptin (100 mg qd ) was efficacious at decreasing FPG and HbA 1c as in all previous studies of >4-wk duration (1-3, 6-9, 33-36). In addition, as in previous trials, vildagliptin generally increased plasma levels of intact GLP-1, reduced prandial glucose and glucagon, and increased insulin secretion relative to glucose when these measures were made. These changes were judged to be independent of the patient's severity of disease or treatment duration (9-11, 13, 37-40) .
In summary, the present study demonstrated that in patients with T2DM, the DPP-4 inhibitor vildagliptin improved the ability of both α-and β-cells to sense and respond appropriately to placebo.
